A variability in PSMA expression after enzalutamide medication was also noted by Aggarwal et al., with an increase in almost half of analyzed target lesions in n = 8 patients with prostate cancer (4 castration-resistant and 4 castration-sensitive patients) [24]. This evidence concerns the gene FOLH1 and Familial prostate cancer.